REVVITY, INC.

Previous wording

Our overall revenue in the third quarter of fiscal year 2025 was $698.9 million which increased by $14.9 million, or 2%, as compared to the third quarter of fiscal year 2024, reflecting an increase of $10.9 million, or 3%, in our Diagnostics segment revenue, and an increase of $4.0 million, or 1%, in our Life Sciences segment revenue. The increase in our Diagnostics segment revenue for the third quarter of fiscal year 2025 was driven primarily by our Reproductive Health business. The increase in our Life Sciences segment revenue for the third quarter of fiscal year 2025 was driven by increased revenue in our Software business.

Current wording

Our overall revenue in the first quarter of fiscal year 2026 was $711.1 million which increased by $46.4 million, or 7%, as compared to the first quarter of fiscal year 2025, reflecting an increase of $24.9 million, or 8%, in our Diagnostics segment revenue, and an increase of $21.4 million, or 6%, in our Life Sciences segment revenue. The increase in our Diagnostics segment revenue for the first quarter of fiscal year 2026 was driven by both our Reproductive Health business and favorable changes in foreign exchange rates. The increase in our Life Sciences segment revenue for the first quarter of fiscal year 2026 was driven by both our Life Sciences Solutions and Software businesses and the extra fiscal week.

Previous wording

Our consolidated gross margins decreased 266 basis points in the third quarter of fiscal year 2025, as compared to the third quarter of fiscal year 2024, primarily due to increased tariffs, unfavorable changes in foreign exchange rates, and product mix shift. Our consolidated operating margins decreased 263 basis points in the third quarter of fiscal year 2025, as compared to the third quarter of fiscal year 2024, due to gross margin headwinds as discussed above.

Current wording

Our consolidated gross margins decreased 200 basis points from 56.5% to 54.5% in the first quarter of fiscal year 2026, as compared to the first quarter of fiscal year 2025, primarily due to product mix shift, changes in foreign exchange rates, increased tariffs and impact of the extra fiscal week. Our consolidated operating margins decreased from 10.9% to 10.7% in the first quarter of fiscal year 2026, as compared to the first quarter of fiscal year 2025, primarily due to gross margin headwinds and impact of the extra fiscal week, partially offset by productivity and cost containment initiatives.

Previous wording

For a more detailed discussion of our critical accounting policies and estimates, refer to the Notes to our audited consolidated financial statements and Item 7.“Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the fiscal year ended December 29, 2024 (our “2024 Form 10-K”), as filed with the Securities and Exchange Commission. There have been no significant changes in our critical accounting policies and estimates during the nine months ended September 28, 2025.

Current wording

For a more detailed discussion of our critical accounting policies and estimates, refer to the Notes to our audited consolidated financial statements and Item 7.“Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the fiscal year ended December 28, 2025 (our “2025 Form 10-K”), as filed with the Securities and Exchange Commission. There have been no significant changes in our critical accounting policies and estimates during the three months ended April 5, 2026.

Previous wording

Revenue for the three months ended September 28, 2025 was $698.9 million, as compared to $684.0 million for the three months ended September 29, 2024, an increase of $14.9 million, or approximately 2%, which includes an approximate 1% increase in revenue attributable to favorable changes in foreign exchange rates. The analysis in the remainder of this paragraph comp ares segment revenue and includes the effect of foreign exchange rate fluctuations. Life Sciences segment revenue was $342.8 million for the three months ended September 28, 2025, as compared to $338.8 million for the three months ended September 29, 2024, an increase of $4.0 million, or 1%, driven by an increase of $8.9 million in Software revenue and a decrease of $4.9 million in Life Sciences Solutions revenue. Diagnostics segment revenue was $356.1 million for the three months ended September 28, 2025, as compared to $345.2 million for the three months ended September 29, 2024, an increase of $10.9 million, or 3%, due to an increase of $9.7 million in Reproductive Health revenue and an increase of $1.2 million in Immunodiagnostics revenue.

Current wording

Revenue for the three months ended April 5, 2026 was $711.1 million, as compared to $664.8 million for the three months ended March 30, 2025, an increase of $46.4 million, or 7%, which includesa 3% increase in revenue attributable to favorable changes in foreign exchange rates and a 1%increase in revenue attributable to acquisitions. The analysis in the remainder of this paragraph comp ares segment revenue and includes the effect of foreign exchange rate fluctuations. Life Sciences segment revenue was $361.8 million for the three months ended April 5, 2026, as compared to $340.4 million for the three months ended March 30, 2025, an increase of $21.4 million, or 6%, driven by an increase of $13.5 million in Life Sciences Solutions revenue and an increase of $7.9 million in Software revenue and the extra fiscal week. Diagnostics segment revenue was $349.3 million for the three months ended April 5, 2026, as compared to $324.4 million for the three months ended March 30, 2025, an increase of $24.9 million, or 8%, due to an increase of $20.6 million in Reproductive Health revenue and an increase of $4.3 million in Immunodiagnostics revenue.

Previous wording

Cost of revenue for the three months ended September 28, 2025 was $324.3 million, as compared to $299.2 million for the three months ended September 29, 2024, an increase of $25.1 million, or 8%. As a percentage of revenue, cost of revenue increased to 46.4% for the three months ended September 28, 2025, from 43.7% for the three months ended September 29, 2024, resulting in a decrease in gross margin of 266 basis points to 53.6% for the three months ended September 28, 2025, from 56.3% for the three months ended September 29, 2024, primarily due to increased tariffs, unfavorable changes in foreign exchange rates, and product mix shift. Stock compensation expense related to awards given to BioLegend employees post-acquisition added an incremental expense of $0.2 million for the three months ended September 29, 2024. Rebranding costs were $0.1 million for the three months ended September 29, 2024. Amortization of intangible assets was $35.3 million for the three months ended September 28, 2025, as compared to $36.4 million for the three months ended September 29, 2024.

Current wording

Cost of revenue for the three months ended April 5, 2026 was $323.5 million, as compared to $289.2 million for the three months ended March 30, 2025, an increase of $34.2 million, or 12%. As a percentage of revenue, cost of revenue increased to 45.5% for the three months ended April 5, 2026, from 43.5% for the three months ended March 30, 2025, resulting in a decrease in gross margin of 200 basis points to 54.5% for the three months ended April 5, 2026, from 56.5% for the three months ended March 30, 2025, primarily due to product mix shift, changes in foreign exchange rates, increased tariffs and impact of the extra fiscal week. Amortization of intangible assets was $35.0 million for the three months ended April 5, 2026, as compared to $34.4 million for the three months ended March 30, 2025.

Previous wording

Selling, general and administrative expenses for the three months ended September 28, 2025 were $241.9 million, as compared to $237.5 million for the three months ended September 29, 2024, an increase of $4.4 million, or 2%. As a percentage of revenue, selling, general and administrative expenses decreased and were 34.6% for the three months ended September 28, 2025, as compared to 34.7% for the three months ended September 29, 2024. Restructuring and other costs, net, increased, and was $9.9 million for the three months ended September 28, 2025, as compared to decreasing expenses by $0.1 million for the three months ended September 29, 2024. Costs related to our transformation initiatives focused on business process modernization, automation and implementation of global systems to support the new Revvity Business Model (“transformation costs”)added an incremental expense of $5.1 million for the three months ended September 28, 2025. Purchase accounting adjustments increased expenses by $0.2 million for the three months ended September 28, 2025, as compared to decreasing expenses by $0.3 million for the three months ended September 29, 2024, which primarily cons isted of a change in contingent consideration. The above increases in selling, general and administrative expenses compared to prior year were partially offset by a decrease in amortization of intangible assets, which was $48.7 million for the three months ended September 28, 2025, as compared to $53.2 million for the three months ended September 29, 2024. Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, added an incremental expense of $0.3 million for the three months ended September 28, 2025. Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, and stock compensation expense related to the awards given to BioLegend employees post-acquisition, added an incremental expense of $3.9 million for the three months ended September 29, 2024. Significant litigation matters and settlements added an incremental expense of $0.8 million for each of the three months ended September 28, 2025 and September 29, 2024. Excluding the items noted above, selling, general and administrative expenses decreased due to cost controls and productivity gains partially offset by unfavorable changes in foreign exchange rates and investments in digital capabilities and innovation.

Current wording

Selling, general and administrative expenses for the three months ended April 5, 2026 were $253.9 million, as compared to $249.7 million for the three months ended March 30, 2025, an increase of $4.2 million, or 2%. As a percentage of revenue, selling, general and administrative expenses decreased and were 35.7% for the three months ended April 5, 2026, as compared to 37.6% for the three months ended March 30, 2025. Amortization of intangible assets increased and was $50.1 million for the three months ended April 5, 2026, as compared to $48.3 million for the three months ended March 30, 2025. Restructuring and other costs increased and was $10.7 million for the three months ended April 5, 2026, as compared to $3.2 million for the three months ended March 30, 2025. Restructuring and other costs in the first quarter of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. In the first quarter of fiscal year 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of our workforce. Transformation costs were $0.8 millionfor the three months ended April 5, 2026. Purchase accounting adjustments decreased expenses by $0.1 million for the three months ended April 5, 2026, which primarily consisted of a change in contingent consideration, as compared to $0.4 million for the three months ended March 30, 2025. Costs for significant environmental matters decreased expenses by $1.2 million for the three months ended March 30, 2025. The above increases were also partially offset by a decrease in significant litigation matters and settlements, which was $0.1 million for the three months ended April 5, 2026, as compared to $10.6 million for the three months ended March 30, 2025. Disposition of businesses and assets, net decreased expenses by $5.1 million for the three months ended April 5, 2026. Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, decreased and was $0.3 million for the three months ended April 5, 2026, as compared to $2.5 million for the three months ended March 30, 2025. Excluding the items noted above, selling, general and administrative expenses increased labor costs due to the extra fiscal week in the current quarter as compared to the same period in the prior year and employee incentive compensation.

Previous wording

Research and development expenses for the three months ended September 28, 2025 were $50.8 million, as compared to $49.1 million for the three months ended September 29, 2024, an increase of $1.7 million, or 3%. As a percentage of revenue, research and development expenses increased and were 7.3% for the three months ended September 28, 2025, as compared to 7.2% for the three months ended September 29, 2024. The increase in research and development expenses was primarily driven by unfavorable changes in foreign exchange rates and our investments in new product development. Stock compensation expense related to awards given to BioLegend employees post-acquisition added an incremental expense of $0.7 million for the three months ended September 29, 2024.

Current wording

Research and development expenses for the three months ended April 5, 2026 were $57.9 million, as compared to $53.6 million for the three months ended March 30, 2025, an increase of $4.3 million, or 8%. As a percentage of revenue, research and development expenses were flat at 8.1% for both the three months ended April 5, 2026 and the three months ended March 30, 2025. The increase in research and development expenses was primarily driven by our investments in new product development and increased labor costs due to the extra fiscal week.

Previous wording

Interest and Other Expense (Income), Net

Current wording

Interest and Other Expense, Net

Previous wording

Interest and other expense (income), net, consisted of the following:

Current wording

Interest and other expense, net, consisted of the following:

Previous wording

The decrease in interest income for the three and nine months ended September 28, 2025 as compared to the three and nine months ended September 29, 2024 was primarily due to a decrease in marketable securities and short-term investments. Interest expense was lower for the three and nine months ended September 28, 2025 as compared to the same period in prior year primarily due to a lower debt balance as a result of the repayment of senior unsecured notes that matured in September 2024.

Current wording

The decrease in interest income for the three months ended April 5, 2026 as compared to the three months ended March 30, 2025 was primarily due to a decrease in marketable securities and short-term investments. Interest expense was higher for the three months ended April 5, 2026 as compared to the same period in the prior year primarily due to the extra fiscal week in the current quarter, which resulted in one additional week of accrued interest as compared to the quarter ended March 30, 2025.

Previous wording

The provision for income taxes from continuing operations was $8.5 million for the three months ended September 28, 2025, as compared to $7.0 million for the three months ended September 29, 2024. The provision for income taxes from continuing operations was $32.6 million for thenine months ended September 28, 2025, as compared to $26.9 million for thenine months ended September 29, 2024.

Current wording

The provision for income taxes from continuing operations was $9.1 million for the three months ended April 5, 2026, as compared to $10.7 million for the three months ended March 30, 2025.

Previous wording

The effective tax rate from continuing operations was 15.2% and 18.5% for the three and nine months ended September 28, 2025, as compared to 6.9% and 12.1% for the three and nine months ended September 29, 2024. The effective tax rate for the three and nine months ended September 28, 2025 was higher as compared to the three and nine months ended September 29, 2024 primarily due to net favorable impacts of prior year true-ups recorded in fiscal year 2024 in foreign locations of $7.1 million. We expect that the effective tax rate on continuing operations, before discrete items, will be approximately 20% during fiscal year 2025.

Current wording

The effective tax rate from continuing operations was 18.2% for the three months ended April 5, 2026, as compared to 20.5% for the three months ended March 30, 2025. The effective tax rate for the three months ended April 5, 2026 was lower primarily due to net favorable impacts of prior year true-ups recorded in fiscal year 2026 in foreign locations of $1.0 million as compared to fiscal year 2025. We expect that the effective tax rate on continuing operations, before discrete items, will be approximately 20% during fiscal year 2026.

Previous wording

Revenue for the three months ended September 28, 2025 was $342.8 million, as compared to $338.8 million for the three months ended September 29, 2024, an increase of $4.0 million, or 1%, which includes an approximate 1% increase in revenue attributable to favorable changes in foreign exchange rates. The increase in our Life Sciences segment revenue during the three months ended September 28, 2025 was driven by an increase of $8.9 million in Software revenue, partially offset by a decrease of $4.9 million in Life Sciences Solutions revenue.

Current wording

Revenue for the three months ended April 5, 2026 was $361.8 million, as compared to $340.4 million for the three months ended March 30, 2025, an increase of $21.4 million, or 6%, which includes a 2%increase in revenue attributable to acquisitions and divestituresand a 2% increase in revenue attributable to favorable changes in foreign exchange rates. The increase in our Life Sciences segment revenue during the three months ended April 5, 2026 was driven by an increase of $13.5 million in Life Sciences Solutions revenue and an increase of $7.9 million in Software revenue and the extra fiscal week.

Previous wording

Segment operating income for the three months ended September 28, 2025 was $101.0 million, as compared to $110.6 million for the three months ended September 29, 2024, a decrease of $9.5 million, or 9%. Segment operating margin decreased 316 basis points in the three months ended September 28, 2025, as compared to the three months ended September 29, 2024, primarily due to increased tariffs, unfavorable changes in foreign exchange rates, and product mix shift.

Current wording

Segment operating income for the three months ended April 5, 2026 was $104.0 million, as compared to $105.7 million for the three months ended March 30, 2025, a decrease of $1.7 million, or 2%. Segment operating margin decreased 240 basis points in the three months ended April 5, 2026, as compared to the three months ended March 30, 2025, primarily due to product mix shift, strategic investments in software and new product development and impact of the extra fiscal week.

Previous wording

Revenue for the three months ended September 28, 2025 was $356.1 million, as compared to $345.2 million for the three months ended September 29, 2024, an increase of $10.9 million, or 3%, which includes an approximate 2% increase in revenue attributable to favorable changes in foreign exchange rates. Theincrease in our Diagnostics segment revenue duringthe three months ended September 28, 2025 was driven by an increase of $9.7 million in Reproductive Health revenue andan increase of $1.2 million in Immunodiagnostics revenue.

Current wording

Revenue for the three months ended April 5, 2026 was $349.3 million, as compared to $324.4 million for the three months ended March 30, 2025, an increase of $24.9 million, or 8%, which includes a 4% increase in revenue attributable to favorable changes in foreign exchange rates. Theincrease in our Diagnostics segment revenue duringthe three months ended April 5, 2026 was driven by an increase of $20.6 million in Reproductive Health revenue and an increase of $4.3 million in Immunodiagnostics revenue.

Previous wording

Segment operating incomefor the three months ended September 28, 2025 was $89.4 million, as compared to $93.8 millionfor the three months ended September 29, 2024, a decrease of $4.5 million, or 5%. Segment operating margin decreased 209 basis points in the three months ended September 28, 2025, as compared to the three months ended September 29, 2024, primarily due to increased tariffs, unfavorable changes in foreign exchange rates, product mix shift, and investments in new product development and digital capabilities.

Current wording

Segment operating incomefor the three months ended April 5, 2026 was $76.1 million, as compared to $74.0 millionfor the three months ended March 30, 2025, an increase of $2.1 million, or 3%. Segment operating margin decreased 100 basis points in the three months ended April 5, 2026, as compared to the three months ended March 30, 2025, primarily due to product mix shift, changes in foreign exchange rates, increased tariffs and impact of the extra fiscal week.

Previous wording

At September 28, 2025, we had cash and cash equivalents of$931.4 million, of which $540.0 million was held by our non-U.S. subsidiaries, and we had$1.5 billion of borrowing capacity available under our senior unsecured revolving credit facility. We use a variety of cash redeployment and financing strategies to ensure that our worldwide cash is available in the locations in which it is needed.

Current wording

At April 5, 2026, we had cash and cash equivalents of$860.3 million, of which $518.3 million was held by our non-U.S. subsidiaries, and we had$1.5 billion of borrowing capacity available under our senior unsecured revolving credit facility. We use a variety of cash redeployment and financing strategies to ensure that our worldwide cash is available in the locations in which it is needed.

Previous wording

On October 24, 2024, our Board of Directors(our“Board”)authorized us to repurchase shares of common stock for an aggregate amount up to $1.0 billion under a stock repurchase program (the “Repurchase Program”). As of September 28, 2025,$209.7 million remained available for aggregate repurchases of shares under the Repurchase Program. Subsequent to the third quarter of fiscal year 2025, we repurchased 515,232 shares of common stock under the Repurchase Program at an aggregate cost of $47.5 million. On October 23, 2025, the Repurchase Program was terminated by our Board and our Board authorized us to repurchase shares of common stock for an aggregate amount up to $1.0 billion under a new stock repurchase program (the “New Repurchase Program”). No shares remain available for repurchase under the Repurchase Program due to its termination. The New Repurchase Program will expire on October 22, 2027 unless terminated earlier by our Board and may be suspended or discontinued at any time. Subsequent to October 23, 2025, we repurchased 172,642 shares of common stock under the New Repurchase Program at an aggregate cost of $16.5 million. If we continue to repurchase shares, the New Repurchase Program will be funded using our existing financial resources, including cash and cash equivalents, and our existing senior unsecured revolving credit facility.

Current wording

On October 23, 2025, our Board of Directors (our “Board”) authorized us to repurchase shares of common stock for an aggregate amount up to $1.0 billion under a stock repurchase program (the “Repurchase Program”). The Repurchase Program will expire on October 22, 2027 unless terminated earlier by our Board and may be suspended or discontinued at anytime. During the three months ended April 5, 2026, we repurchased 784,142 shares of common stock under the Repurchase Program for an aggregate cost of $79.0 million. As of April 5, 2026,$800.5 million remained available for aggregate repurchases ofshares under the Repurchase Program. Subsequent to the first quarter of fiscal year 2026, we repurchased 93,303 shares of common stock under the Repurchase Program at an aggregate cost of $7.8 million. If we continue to repurchase shares, the Repurchase Program will be funded using our existing financial resources, including cash and cash equivalents, and our existing senior unsecured revolving credit facility.

Previous wording

As of September 28, 2025, we may have to pay contingent consideration related to acquisitions with open contingency periods of up to $77.9 million. As of September 28, 2025, we have recorded contingent consideration obligations of $19.2 million, of which $5.0 million was recorded in accrued expenses and other current liabilities, and $14.2 million was recorded in long-term liabilities. The maximum earnout period for acquisitions with open contingency periods is 6.2 years from September 28, 2025, and the remaining weighted average expected earnout period at September 28, 2025 was 3.8 years.

Current wording

As of April 5, 2026, we may have to pay contingent consideration related to acquisi tions with open contingency periods of up to $81.6 million. As of April 5, 2026, we have recorded contingent consideration obligations of $25.0 million, of which $4.0 million was recorded in accrued expenses and other current liabilities, and $21.0 million was recorded in long-term liabilities. The maximum earnout period for acquisitions with open contingency periods is 5.7 years from April 5, 2026, and the remaining weighted average expected earnout period at April 5, 2026 was 3.2 years.

Previous wording

Operating Activities. Net cash provided by operating activities of ourcontinuing operations was $407.0 million for the nine months ended September 28, 2025, as compared to $489.5 million for the nine months ended September 29, 2024, a decrease of $82.5 million, primarily due to timing of collections during the nine months ended September 28, 2025 as compared to the nine months ended September 29, 2024. The cash provided by operating activities for the nine months ended September 28, 2025 was principally a result of income from continuing operations of $144.1 million, adjustments for non-cash charges aggregating to $360.8 million, including depreciation and amortization of $302.3 million, and a net cash decrease in working capital of $97.9 million. The cash provided by operating activities for the nine months ended September 29, 2024 was principally a result of income from continuing operations of $194.7 million, and adjustments for non-cash charges aggregating to $373.7 million, including depreciation and amortization of $322.8 million, and a net cash decrease in working capital of $78.9 million.

Current wording

Operating Activities. Net cash provided by operating activities of ourcontinuing operations was $125.9 million for the three months ended April 5, 2026, as compared to $134.1 million for the three months ended March 30, 2025, a decrease of $8.2 million. The cash provided by operating activities for the three months ended April 5, 2026 was principally a result of adjustments for non-cash charges aggregating to $124.7 million, including depreciation and amortization of $105.1 million, income from continuing operations of $40.9 million, and a net cash decrease in working capital of $39.7 million, primarily due to timing of collections, inventory purchases and employee incentive compensation payout. The cash provided by operating activities for the three months ended March 30, 2025 was principally a result of adjustments for non-cash charges aggregating to $105.7 million, including depreciation and amortization of $97.4 million, income from continuing operations of $41.7 million, and a net cash decrease in working capital of $13.3 million.

Previous wording

Investing Activities. Net cash used in investing activitiesof our continuing operationswas $53.2 million for the nine months ended September 28, 2025, as compared to net cash provided of $646.0 million for the nine months ended September 29, 2024, an increase of $699.1 million in net cash used in investing activities. During the nine months ended September 28, 2025, net cash used for capital expenditures was $53.4 million, as compared to $62.2 million for the nine months ended September 29, 2024. The cash used in investing activities during the nine months ended September 28, 2025 was partially offset by $0.2 million proceeds from disposition of businesses and assets. During the nine months ended September 29, 2024, proceeds from maturity of U.S. treasury securities were $710.0 million and proceeds from investments and notes receivables were $2.5 million, which were partially offset by purchases of investments and notes receivables totaling $4.3 million.

Current wording

Investing Activities. Net cash used in investing activitiesof our continuing operationswas $78.3 million for the three months ended April 5, 2026, as compared to $15.8 million for the three months ended March 30, 2025, an increase of $62.5 million primarily due to cash paid for acquisitions, net of cash acquired of $67.3 million during the three months ended April 5, 2026. During the three months ended April 5, 2026, net cash used for capital expenditures was $19.8 million, as compared to $16.0 million for the three months ended March 30, 2025. During the three months ended April 5, 2026, purchases of investments and notes receivables were $1.1 million. The cash used in investing activities during the three months ended April 5, 2026 was partially offset by $0.2 million proceeds from disposition of businesses and assets, remaining flat compared to the three months ended March 30, 2025. During the three months ended April 5, 2026, proceeds from disposition of property, plant and equipment amounted to $9.0 million. During the three months ended April 5, 2026, proceeds from investments and notes receivable amounted to $0.7 million.

Previous wording

Financing Activities. Net cash used in financing activities was $681.2 million for the nine months ended September 28, 2025, as compared to $935.2 million for the nine months ended September 29, 2024, a decrease of $254.0 million. During the nine months ended September 28, 2025, we repurchased shares of our common stock for a total cost of $652.5 million, as compared to $184.4 million in the prior year period. We paid $24.8 million in dividends for the nine months ended September 28, 2025, as compared to $25.9 million for the nine months ended September 29, 2024. During the nine months ended September 28, 2025, we made net payments of$2.6 millionon debts, as compared to $722.3 million during the nine months ended September 29, 2024. We paid $3.8 million for acquisition-related contingent consideration during the nine months ended September 28, 2025, as compared to $8.8 million in the prior year period. The cash used in financing activities during the nine months ended September 28, 2025 was partially offset by proceeds from the issuance of common stock under our stock plans of $2.6 million during the nine months ended September 28, 2025, as compared to $6.2 million for the nine months ended September 29, 2024.

Current wording

Financing Activities. Net cash used in financing activities was $88.9 million for the three months ended April 5, 2026, as compared to $163.7 million for the three months ended March 30, 2025, a decrease of $74.8 million. During the three months ended April 5, 2026, we repurchased shares of our common stock for a total cost of $86.5 million, as compared to $153.6 million in the prior year period. We paid $7.8 million in dividends for the three months ended April 5, 2026, as compared to $8.4 million for the three months ended March 30, 2025. During the three months ended March 30, 2025, we made net payments of$2.5 millionon debts. We paid $1.8 million for acquisition-related contingent consideration during the three months ended March 30, 2025. The cash used in financing activities during the three months ended April 5, 2026 was partially offset by proceeds from the issuance of common stock under our stock plans of $5.4 million during the three months ended April 5, 2026, as compared to $2.6 million for the three months ended March 30, 2025.

Previous wording

Our outstanding€500,000 Principal 1.875% Senior Unsecured Notes due in 2026(“2026 Notes”) will maturein July 2026. We expect to repay the 2026 Notes with our existing cash on hand or drawings from our senior unsecured revolving credit facility, or a combination thereof.

Current wording

Our outstanding€500,000 Principal 1.875% Senior Unsecured Notes due in 2026(the “2026 Notes”) will maturein July 2026. We expect to repay the 2026 Notes with our existing cash on hand or borrowings under our senior unsecured revolving credit facility, or a combination thereof. See Note 7, Debt, in the Notes to Condensed Consolidated Financial Statements and Note 13, Debt, to our audited consolidated financial statements in the 2025 Form 10-Kfor a detailed discussion of our borrowing arrangements.

Previous wording

Our Board declared a regular quarterly cash dividend of $0.07 per share for the first three quarters of fiscal year 2025 and in each quarter of fiscal year 2024. At September 28, 2025, we had accrued $8.0 million for dividends declared on July 24, 2025 for the third quarter of fiscal year 2025 that will be paid in November 2025. On October 23, 2025, we announced that our Board had declared a quarterly dividend of $0.07 per share for the fourth quarter of fiscal year 2025 that will be payable in February 2026. In the future, our Board may determine to reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Current wording

Our Board declared a regular quarterly cash dividend of $0.07 per share forthe first quarterof fiscal year 2026 and in each quarter of fiscal year 2025. At April 5, 2026, we had accrued $7.8 million for dividends declared on January 26, 2026 for the first quarter of fiscal year 2026 that were paid in May 2026. On April 30, 2026, we announced that our Board had declared a quarterly dividend of $0.07 per share for the second quarter of fiscal year 2026 that will be payable in August 2026. In the future, our Board may determine to reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Previous wording

See Note 1, Nature of Operations and Accounting Policies, to our audited consolidated financial statements in the 2024 Form 10-K for a summary of recently adopted new accounting pronouncements during the fiscal year ended December 29, 2024. We have not adopted any new accounting pronouncements during thenine months ended September 28, 2025.

Current wording

See Note 1, Nature of Operations and Accounting Policies, to our audited consolidated financial statements in the 2025 Form 10-K for a summary of recently adopted new accounting pronouncements during the fiscal year ended December 28, 2025. We have not adopted any new accounting pronouncements during the three months ended April 5, 2026.